A phase 1/2, open-label, two-part dose escalation and expansion clinical study of JBI-778 to evaluate the safety profile, pharmacokinetics, optimal dosing of the drug in patients with stable brain metastasis and high-grade gliomas

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 16 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JBI-778 (Primary)
Indications Brain metastases; Glioma
Focus Therapeutic Use
Sponsors Jubilant Therapeutics

Most Recent Events

14 Feb 2023 According to a Jubilant Therapeutics media release, this trial is anticipated to start during the second half of 2023.
17 Aug 2022 New trial record
03 Aug 2022 According to a Jubilant Therapeutics media release, the USA Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) for JBI-778.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight